This Mangoceuticals Insider Increased Their Holding In The Last Year

editorial-team@simplywallst.com (Simply Wall St)
2 min read
0
In this article:

Viewing insider transactions for Mangoceuticals, Inc.'s (NASDAQ:MGRX ) over the last year, we see that insiders were net buyers. This means that a larger number of shares were purchased by insiders in relation to shares sold.

Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.

View our latest analysis for Mangoceuticals

The Last 12 Months Of Insider Transactions At Mangoceuticals

In fact, the recent purchase by was the biggest purchase of Mangoceuticals shares made by an insider individual in the last twelve months, according to our records. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$0.27. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Mangoceuticals insiders own 43% of the company, currently worth about US$2.8m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

So What Does This Data Suggest About Mangoceuticals Insiders?

It doesn't really mean much that no insider has traded Mangoceuticals shares in the last quarter. It's heartening that insiders own plenty of stock, but we'd like to see more insider buying, since the last year of Mangoceuticals insider transactions don't fill us with confidence. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Mangoceuticals. Case in point: We've spotted 5 warning signs for Mangoceuticals you should be aware of, and 4 of these are a bit unpleasant.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Advertisement

Recommended Stories

  • Virgin Galactic (SPCE) Stock Sinks As Market Gains: What You Should Know

    The latest trading day saw Virgin Galactic (SPCE) settling at $0.88, representing a -0.41% change from its previous close.

  • Bitcoin Plunges. Here’s Why and How Far Prices Could Fall.

    Bitcoin sells off alongside stocks amid wider market jitters. But now the technical backdrop for cryptos is even weaker.

  • Pfizer lifts profit view on cost cuts, smaller drop in demand for COVID products

    Shares of the U.S. drugmaker have lost 11% of their value this year on worries over its growth after the pandemic as billions of dollars in COVID vaccine and treatment sales evaporated. Pfizer reiterated its annual revenue forecast of $8 billion from the sale of COVID-19 shot Comirnaty and anti-viral treatment Paxlovid. Revenue from Comirnaty, for which it partners with Germany's BioNTech, continues to perform consistently with its expectations, Pfizer said.

  • Like Realty Income? This Competitor Has an Even Better Dividend Track Record

    Realty Income is the leader in the net lease REIT industry, but there's an important area where it is not No. 1.

  • Stock market today: S&P 500 futures slide with Fed's Powell in the spotlight

    Fed day arrives with the focus on what clues Powell will offer to the chances for rate cuts this year.

  • CVS cuts 2024 profit forecast as insurance unit faces soaring medical costs

    The U.S. healthcare giant cut its per-share adjusted earnings forecast for 2024 to at least $7.00 from at least $8.30, adding it anticipates the surge in medical procedures at its unit that houses health insurer Aetna to persist. U.S. health insurers have had to contend with rising medical costs over the past few quarters following higher demand for procedures, especially among older adults, that were delayed during the pandemic. CVS said in February it was seeing a rise in hip and knee surgeries, medical services related to the eyes, dental work, as well as vaccinations including the RSV shot during the last three months of 2023.

  • Crypto washout sends bitcoin below $58,000 ahead of Fed decision

    Bitcoin slid by almost 6% on Wednesday, having posted its worst monthly performance in April since late 2022, as investors pulled money out of cryptocurrencies ahead of an interest rate decision by the Federal Reserve later. The value of the world's most traded cryptocurrency fell by nearly 16% in April, as investors booked profits on a sizzling rally that has taken the price to record highs above $70,000. The price of bitcoin is now a full 22% below March's record of $73,803, technically putting it in a bear market.

  • Artificial Intelligence (AI) Isn't Going Anywhere. Here Are 3 Stocks to Buy and Hold for Decades.

    These companies are behind the creation and power of AI models that are changing our world.

  • SoFi Stock: Time to Abandon Ship or Buy the Dip?

    SoFi's stock is dropping like a rock, which may be an opportunity.

  • 3M Is ‘Resetting’ Its Dividend. Why Its Stock Is Soaring.

    3M’s quarterly earnings topped Wall Street estimates—a positive—but what the company said about its dividend should get most of the attention. Results included numbers for the recently spun off 3M healthcare business, Solventum That spin was completed on April 1. “We’re resetting the dividend post-spin,” 3M CEO Mike Roman told Barron’s. The company will target about 40% of its free cash flow as annual dividends.